| Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. |
||
| [ <<To the list of latest publications ] | ||
Coluccia, A. M., Gunby,
R. H., Tartari, C. J., Scapozza, L., A
crucial issue in the development of molecularly-targeted anticancer
therapies is the identification of appropriate molecules whose targeting
would result in tumour regression with a minimal level of systemic toxicity.
Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase,
normally expressed at low levels in the nervous system. As a consequence of
chromosomal translocations involving the alk gene (2p23), ALK is also
aberrantly expressed and constitutively activated in ~ 60% of CD30+
anaplastic large cell lymphomas (ALCLs). Due to the selective overexpression
of ALK in tumour cells, its direct involvement in the process of malignant
transformation and its frequent expression in ALCL patients, the authors
recognise ALK as a suitable candidate for the development of molecularly
targeted strategies for the therapeutic treatment of ALK-positive lymphomas.
Strategies targeting ALK directly or indirectly via the inhibition of the
protein networks responsible for ALK oncogenic signalling are discussed. |
||
| [ <<To the list of latest publications ] | ||
